Bronchodilatoreffect shown in vivo for the new RES030-085 substance within RESP9000
Respiratorius AB (publ) announces positive results from an airway study in an animal model with the patented candidate substance RES030-085 for the treatment of COPD and severe asthma. The identification of the substance RES030-085 and its patent application was previously announced in 2018. Going forward, we will group RES030-085 as well as the associated compounds in the chemical series under the project name RESP9000.The study was carried out by an internationally renowned contract laboratory and in an established animal model (rat) where the experimental animals were exposed to an